ID

33727

Beschrijving

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification; ODM derived from: https://clinicaltrials.gov/show/NCT01664247

Link

https://clinicaltrials.gov/show/NCT01664247

Trefwoorden

Versies (1)
  1. 21-12-18 21-12-18 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

21 december 2018

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Diabetes NCT01664247

Engels

Eligibility Diabetes NCT01664247

1 Formulieren  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01664247
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes
Beschrijving

Diabetes Mellitus, Non-Insulin-Dependent

Datatype

boolean

Alias
UMLS CUI [1]
C0011860
insulin naïve
Beschrijving

Insulin Absent

Datatype

boolean

Alias
UMLS CUI [1,1]
C0021641
UMLS CUI [1,2]
C0332197
ongoing treatment with metformin or metformin in combination with either sulphonylurea (su), glinides, dipeptidyl peptidase-iv (dpp-iv) inhibitors or exenatide (only twice daily (bid))
Beschrijving

Metformin | Combined Modality Therapy | Sulfonylurea | Glinide | Dipeptidyl-Peptidase IV Inhibitors | Exenatide Twice a day

Datatype

boolean

Alias
UMLS CUI [1]
C0025598
UMLS CUI [2]
C0009429
UMLS CUI [3]
C0038766
UMLS CUI [4]
C2266929
UMLS CUI [5]
C1827106
UMLS CUI [6,1]
C0167117
UMLS CUI [6,2]
C0585361
glycosylated haemoglobin (hba1c) (by central laboratory analysis): a. 7.5-10.0 % (both inclusive) for subjects on metformin monotherapy, b. 7.0-9.0 % (both inclusive) for subjects on metformin in combination with either su, glinides, dpp-iv inhibitors or exenatide (only bid)
Beschrijving

Hemoglobin A1c measurement | Metformin | Combined Modality Therapy | Sulfonylurea | Glinide | DPP-IV Inhibitors | Exenatide Twice a day

Datatype

boolean

Alias
UMLS CUI [1]
C0474680
UMLS CUI [2]
C0025598
UMLS CUI [3]
C0009429
UMLS CUI [4]
C0038766
UMLS CUI [5]
C2266929
UMLS CUI [6]
C1827106
UMLS CUI [7,1]
C0167117
UMLS CUI [7,2]
C0585361
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
treatment with glucose-lowering agent(s) other than stated in the inclusion criteria within 12 weeks
Beschrijving

Hypoglycemic Agents | Exception Inclusion criteria

Datatype

boolean

Alias
UMLS CUI [1]
C0020616
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1512693
calcitonin equal to or above 50 pg/ml
Beschrijving

Calcitonin Dose

Datatype

boolean

Alias
UMLS CUI [1,1]
C0006668
UMLS CUI [1,2]
C0178602
stroke; heart failure new york heart association (nyha) class iii or iv; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within 24 weeks
Beschrijving

Cerebrovascular accident | Heart failure New York Heart Association Classification | Myocardial Infarction | Angina, Unstable | Coronary Artery Bypass Surgery | Angioplasty

Datatype

boolean

Alias
UMLS CUI [1]
C0038454
UMLS CUI [2,1]
C0018801
UMLS CUI [2,2]
C1275491
UMLS CUI [3]
C0027051
UMLS CUI [4]
C0002965
UMLS CUI [5]
C0010055
UMLS CUI [6]
C0162577
current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell carcinoma)
Beschrijving

Malignant Neoplasms | Exception Basal cell carcinoma | Exception Squamous cell carcinoma

Datatype

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0007137
Terug naar het begin van de pagina

Similar models

Eligibility Diabetes NCT01664247

1 Formulieren
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01664247
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Insulin Absent
Item
insulin naïve
boolean
C0021641 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Metformin | Combined Modality Therapy | Sulfonylurea | Glinide | Dipeptidyl-Peptidase IV Inhibitors | Exenatide Twice a day
Item
ongoing treatment with metformin or metformin in combination with either sulphonylurea (su), glinides, dipeptidyl peptidase-iv (dpp-iv) inhibitors or exenatide (only twice daily (bid))
boolean
C0025598 (UMLS CUI [1])
C0009429 (UMLS CUI [2])
C0038766 (UMLS CUI [3])
C2266929 (UMLS CUI [4])
C1827106 (UMLS CUI [5])
C0167117 (UMLS CUI [6,1])
C0585361 (UMLS CUI [6,2])
Hemoglobin A1c measurement | Metformin | Combined Modality Therapy | Sulfonylurea | Glinide | DPP-IV Inhibitors | Exenatide Twice a day
Item
glycosylated haemoglobin (hba1c) (by central laboratory analysis): a. 7.5-10.0 % (both inclusive) for subjects on metformin monotherapy, b. 7.0-9.0 % (both inclusive) for subjects on metformin in combination with either su, glinides, dpp-iv inhibitors or exenatide (only bid)
boolean
C0474680 (UMLS CUI [1])
C0025598 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
C0038766 (UMLS CUI [4])
C2266929 (UMLS CUI [5])
C1827106 (UMLS CUI [6])
C0167117 (UMLS CUI [7,1])
C0585361 (UMLS CUI [7,2])
Item Group
C0680251 (UMLS CUI)
Hypoglycemic Agents | Exception Inclusion criteria
Item
treatment with glucose-lowering agent(s) other than stated in the inclusion criteria within 12 weeks
boolean
C0020616 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1512693 (UMLS CUI [2,2])
Calcitonin Dose
Item
calcitonin equal to or above 50 pg/ml
boolean
C0006668 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
Cerebrovascular accident | Heart failure New York Heart Association Classification | Myocardial Infarction | Angina, Unstable | Coronary Artery Bypass Surgery | Angioplasty
Item
stroke; heart failure new york heart association (nyha) class iii or iv; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within 24 weeks
boolean
C0038454 (UMLS CUI [1])
C0018801 (UMLS CUI [2,1])
C1275491 (UMLS CUI [2,2])
C0027051 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0010055 (UMLS CUI [5])
C0162577 (UMLS CUI [6])
Malignant Neoplasms | Exception Basal cell carcinoma | Exception Squamous cell carcinoma
Item
current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell carcinoma)
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007137 (UMLS CUI [3,2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial